275 related articles for article (PubMed ID: 25965366)
1. PD-L1 blockade for cancer treatment: MEDI4736.
Ibrahim R; Stewart R; Shalabi A
Semin Oncol; 2015 Jun; 42(3):474-83. PubMed ID: 25965366
[TBL] [Abstract][Full Text] [Related]
2. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
Stewart R; Morrow M; Hammond SA; Mulgrew K; Marcus D; Poon E; Watkins A; Mullins S; Chodorge M; Andrews J; Bannister D; Dick E; Crawford N; Parmentier J; Alimzhanov M; Babcook JS; Foltz IN; Buchanan A; Bedian V; Wilkinson RW; McCourt M
Cancer Immunol Res; 2015 Sep; 3(9):1052-62. PubMed ID: 25943534
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 inhibitors.
Sunshine J; Taube JM
Curr Opin Pharmacol; 2015 Aug; 23():32-8. PubMed ID: 26047524
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 inhibition with MPDL3280A for solid tumors.
Cha E; Wallin J; Kowanetz M
Semin Oncol; 2015 Jun; 42(3):484-7. PubMed ID: 25965367
[TBL] [Abstract][Full Text] [Related]
5. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Shin DS; Ribas A
Curr Opin Immunol; 2015 Apr; 33():23-35. PubMed ID: 25621841
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA
J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416
[TBL] [Abstract][Full Text] [Related]
7. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
8. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
9. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
Hamid O; Carvajal RD
Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
[TBL] [Abstract][Full Text] [Related]
10. B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction.
Gettinger S; Herbst RS
Cancer J; 2014; 20(4):281-9. PubMed ID: 25098289
[TBL] [Abstract][Full Text] [Related]
11. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.
Merelli B; Massi D; Cattaneo L; Mandalà M
Crit Rev Oncol Hematol; 2014 Jan; 89(1):140-65. PubMed ID: 24029602
[TBL] [Abstract][Full Text] [Related]
12. Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy.
Sznol M
Cancer J; 2014; 20(4):290-5. PubMed ID: 25098290
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive markers for the new immunotherapies.
Mahoney KM; Atkins MB
Oncology (Williston Park); 2014 Nov; 28 Suppl 3():39-48. PubMed ID: 25384886
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.
Hersey P; Gowrishankar K
Future Oncol; 2015; 11(1):133-40. PubMed ID: 25572788
[TBL] [Abstract][Full Text] [Related]
15. Antagonists of PD-1 and PD-L1 in Cancer Treatment.
Lipson EJ; Forde PM; Hammers HJ; Emens LA; Taube JM; Topalian SL
Semin Oncol; 2015 Aug; 42(4):587-600. PubMed ID: 26320063
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab: targeting PD-1 to bolster antitumor immunity.
Brahmer JR; Hammers H; Lipson EJ
Future Oncol; 2015; 11(9):1307-26. PubMed ID: 25798726
[TBL] [Abstract][Full Text] [Related]
17. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor.
Deng R; Bumbaca D; Pastuskovas CV; Boswell CA; West D; Cowan KJ; Chiu H; McBride J; Johnson C; Xin Y; Koeppen H; Leabman M; Iyer S
MAbs; 2016; 8(3):593-603. PubMed ID: 26918260
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.
Chen DS; Irving BA; Hodi FS
Clin Cancer Res; 2012 Dec; 18(24):6580-7. PubMed ID: 23087408
[TBL] [Abstract][Full Text] [Related]
19. Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions.
Pal SK; Hu A; Chang M; Figlin RA
Clin Adv Hematol Oncol; 2014 Feb; 12(2):90-9. PubMed ID: 24892254
[TBL] [Abstract][Full Text] [Related]
20. The immunoinhibitory B7-H1 molecule as a potential target in cancer: killing many birds with one stone.
Afreen S; Dermime S
Hematol Oncol Stem Cell Ther; 2014 Mar; 7(1):1-17. PubMed ID: 24398144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
